Trial · NCT00794313

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

NCT00794313, Not applicable, Terminated, Oregon Health and Science University; results first posted 2017-05-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease. Trials, record NCT00794313. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00794313

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
NCT number: NCT00794313
Status: Terminated
Phases: Not applicable
Enrollment: 3 participants, actual
Lead sponsor: Oregon Health and Science University
Conditions: Parkinson's Disease
Interventions: Amantadine 300 mg, Topiramate, Sugar Pill
First posted: 2008-11-20
Last updated: 2018-02-01
Results first posted: 2017-05-11

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Forceplate AUC	Every 1/2 hour for 8 hour levodopa cycle	Area under the curve for the root mean squared velocity in the anterior-posterior direction as measured by a forceplate.
Secondary	Modified Abnormal Involuntary Movement Scale Area Under the Curve	Measured every 1/2 hour for a levodopa dose cycle (starting 1 hour prior to infusion and ending 4 hours post 2-hour infusion)	Area under the curve computed for whole body (total) mAIMS (Modified Abnormal Involuntary Movement Scale) scores at each time measurement. This is a commonly utilized scale that is completed by an observer who judges the severity of levodopa induced dyskinesia (LID) in 7 body parts (face, neck, trunk, both legs, and both arms). All body parts are rated separately on this 0 (none) to 4 (severe - markedly impairs activities) scale. Thus, the total score can range from 0 - 28 with 28 indicating the most severe LID. mAIMS ratings occur as the subject performs the cognitive task while standing on the force plate. mAIMS ratings are made every half hour during the levodopa (LD) dose cycle.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Forceplate AUC	Every 1/2 hour for 8 hour levodopa cycle	triple cross-over study design.	(meters/second)*hours	MEAN
SECONDARY	Modified Abnormal Involuntary Movement Scale Area Under the Curve	Measured every 1/2 hour for a levodopa dose cycle (starting 1 hour prior to infusion and ending 4 hours post 2-hour infusion)		Units on a Scale * Hours	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Forceplate AUC	Amantadine	10.4	Standard Deviation 5.6	(meters/second)*hours
Forceplate AUC	Amantadine Plus Topiramate	9.4	Standard Deviation 3.5	(meters/second)*hours
Forceplate AUC	Sugar Pill	19.1	Standard Deviation 18.8	(meters/second)*hours
Modified Abnormal Involuntary Movement Scale Area Under the Curve	Amantadine	4.0	Standard Deviation 2.9	Units on a Scale * Hours
Modified Abnormal Involuntary Movement Scale Area Under the Curve	Amantadine Plus Topiramate	5.3	Standard Deviation 4.4	Units on a Scale * Hours
Modified Abnormal Involuntary Movement Scale Area Under the Curve	Sugar Pill	8.5	Standard Deviation 8.6	Units on a Scale * Hours

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Amantadine, Then Amantadine + Topiramate, Then Placebo	1
Overall Study	STARTED	Amantadine + Topiramate, Then Placebo, Then Amantadine	1
Overall Study	STARTED	Placebo, Then Amantadine, Then Amantadine + Topiramate	1
Overall Study	COMPLETED	Amantadine, Then Amantadine + Topiramate, Then Placebo	1
Overall Study	COMPLETED	Amantadine + Topiramate, Then Placebo, Then Amantadine	1
Overall Study	COMPLETED	Placebo, Then Amantadine, Then Amantadine + Topiramate	1
Overall Study	NOT COMPLETED	Amantadine, Then Amantadine + Topiramate, Then Placebo	0
Overall Study	NOT COMPLETED	Amantadine + Topiramate, Then Placebo, Then Amantadine	0
Overall Study	NOT COMPLETED	Placebo, Then Amantadine, Then Amantadine + Topiramate	0

Source ClinicalTrials.gov

Adverse events18

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	SOMNOLENCE	Nervous system disorders	Amantadine	0	3	0
other	SOMNOLENCE	Nervous system disorders	Amantadine Plus Topiramate	1	3	1
other	SOMNOLENCE	Nervous system disorders	Sugar Pill	0	3	0
other	HALLUCINATIONS	Psychiatric disorders	Amantadine	0	3	0
other	HALLUCINATIONS	Psychiatric disorders	Amantadine Plus Topiramate	1	3	1
other	HALLUCINATIONS	Psychiatric disorders	Sugar Pill	1	3	1
other	NAUSEA	Gastrointestinal disorders	Amantadine	0	3	0
other	NAUSEA	Gastrointestinal disorders	Amantadine Plus Topiramate	0	3	0
other	NAUSEA	Gastrointestinal disorders	Sugar Pill	1	3	1
other	FATIGUE	General disorders	Amantadine	0	3	0

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Amantadine
Total, all-cause mortality	Amantadine Plus Topiramate
Total, all-cause mortality	Sugar Pill
Total, other adverse events	Amantadine	0	3
Total, other adverse events	Amantadine Plus Topiramate	2	3
Total, other adverse events	Sugar Pill	3	3
Total, serious adverse events	Amantadine	0	3
Total, serious adverse events	Amantadine Plus Topiramate	0	3
Total, serious adverse events	Sugar Pill	0	3

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
9595981	BACKGROUND	PubMed
10348468	BACKGROUND	PubMed
10803797	BACKGROUND	PubMed
11391748	BACKGROUND	PubMed
16154788	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00794313

GET https://conductscience.org/api/trials/v1/NCT00794313/registered

API reference For AI assistants